American Society of Clinical Oncology
225 Reinekers Lane
Suite 650
Alexandria
Virginia
22314
United States
Tel: 703-299-0150
Fax: 703-299-1044
Website: http://www.asco.org/
Email: asco@asco.org
2045 articles with American Society of Clinical Oncology
-
Isofol Announces Recent Advisory Board Meeting Covering Development Plan for Arfolitixorin
7/15/2019
Isofol Medical AB, announced the outcome of an advisory board meeting held to discuss the current status and ongoing strategy for the development of arfolitixorin, the company's proprietary drug candidate being studied in the global pivotal Phase 3 AGENT study for advanced colorectal cancer.
-
Innovent Provide Key Results Update of Several Clinical Studies at 2019 ASCO Annual Meeting
7/3/2019
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, presented the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma with sintilimab, co-developed with Eli Lilly and Company and key data from six other clinical studies were presented at the 55th Annual Meeting of the American Society of Clinical Oncology by oral presentation and posters.
-
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings
6/18/2019
Innovent Biologics, Inc. announced that the clinical results of CT103A, the potential best-in-class therapy of fully-human BCMA CAR-T co-developed by Innovent and Nanjing IASO Biotherapeutics, was presented by oral presentation and poster at two of the most prestigious clinical meetings in the worlds of hematology and oncology, the 24th Congress of the European Hematological Society and the American Society of Clinical Oncology Annual Meeting 2019 in Chicago Illinois.
-
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
-
Innovent provides Update on the Results of Sintilimab for the Treatment of Extranodal NK/T Cell Lymphoma by Oral Presentation at ASCO
6/5/2019
Innovent Biologics, Inc. announced that the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma by sintilimab, the anti-PD-1 antibody that co-developed with Eli Lilly and Company, was presented in an oral session at the 55th Annual Meeting of the American Society of Clinical Oncology
-
Amgen Highlights the Versatility of the BiTE® Immuno-Oncology Platform in Multiple Tumour Types at ASCO 2019
6/5/2019
Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO®
-
ASCO called rare cancer treatments the "advance of the year" in oncology.
-
CORRECTING and REPLACING GRAPHIC Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
6/4/2019
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago.
-
Prospective, Multicenter Study of DecisionDx-Melanoma Supports Accuracy and Performance in Prediction of Cutaneous Melanoma Outcomes
6/4/2019
Results from cohort with median follow up of 3.2 years presented at 2019 ASCO Annual Meeting
-
Innovent Provides Updates on Extended Follow-up on Sintilimab for Relapsed/Refractory Classical Hodgkin's Lymphoma
6/4/2019
Innovent Biologics, Inc. announced that the results of extended follow-up on sintilimab, the anti-PD-1 antibody that co-developed with Eli Lilly and Company, for relapsed/refractory classical Hodgkin's lymphoma were presented by poster at the 55th annual meeting of the American Society of Clinical Oncology
-
Innovent Provides Update on Sintilimab in Combination with CAPOX for First-Line Treatment of Patients with Gastric or Gastroesophageal Junction Carcinoma (GC/GEJC)
6/4/2019
Innovent Biologics, Inc. announced that the preliminary results of efficacy and safety of sintilimab, the anti-PD-1 antibody that co-developed with Eli Lilly and Company, in combination with CAPOX in first-line gastric or gastroesophageal junction carcinoma were presented by poster at the 55th annual meeting of the American Society of Clinical Oncology
-
Innovent Provides Update on ctDNA in Predicting Response and Resistance by Anti-PD-1 Therapy in Chinese Relapsed/Refractory Classical Hodgkin Lymphoma
6/4/2019
Innovent Biologics, Inc. announced that the results of circulating tumor DNA for predicting response and resistance by anti-PD-1 therapy in Chinese relapsed/refractory classical Hodgkin lymphoma were presented by poster at the 55th Annual Meeting of the American Society of Clinical Oncology
-
Patients were given Merck’s Keytruda (pembrolizumab) in combination with platinum chemotherapy, Keytruda by itself or chemotherapy by itself. The trial results found that the combination extended survival, and immunotherapy alone also worked well for some patients.
-
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
-
Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit
6/3/2019
Additional Detail in Patients Age 50 or Younger Presented Today in Oral Session at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Data Presented at ASCO Shows Natera's Signatera Test Detects Immunotherapy Treatment Response in Metastatic Cancers
6/3/2019
Results Support Use of New Blood Test as Surrogate Endpoint in Clinical Trials Assessing Immune Checkpoint Inhibitor Effectiveness
-
BERG Presents Key Findings From Two Important Clinical Initiatives At The 2019 ASCO Annual Meeting: BERG's Final Phase 1 Results For BPM 31543 In Chemotherapy-Induced Alopecia And A Clinical Study
6/3/2019
BERG announced the presentation describing key results from two major clinical initiatives at the American Society of Clinical Oncology Annual Meeting in Chicago, being held from May 31th – June 4th.
-
Multiple Myeloma Research Foundation (MMRF) Presents Research Abstracts During 2019 ASCO Annual Meeting
6/3/2019
Abstracts underscore MMRF’s focus on data, innovative clinical trials, and commitment to improving patient outcomes
-
Adastra Pharmaceuticals Announces Positive Interim Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent Malignant Gliomas
6/3/2019
National Cancer Institute (NCI) Study Designed to Investigate Zotiraciclib in Combination with Temozolomide (TMZ) Presented During Poster Session at ASCO 2019
-
Updated Results on Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Squamous Non-Small Cell Lung Cancer (sqNSCLC) at ASCO, Led by Professor Jie He, Dean of the Cancer Hospital of the Chinese Academy of Medical Sciences
6/3/2019
The preliminary results of efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer, led by Professor Jie He, Dean of the Cancer Hospital of the Chinese Academy of Medical Sciences, were presented by poster at the 55th annual meeting of the American Society of Clinical Oncology.